Cedarburg Hauser Adds Controlled Substance Capabilities at Denver Site

Cedarburg Hauser Pharmaceuticals has announced the addition of controlled substance capabilities at its Denver, CO facility. Both of Cedarburg Hauser's facilities, in Colorado and Wisconsin, now hold DEA registrations allowing for the production and analysis of schedule II-V controlled substances.

The kilo-lab manufacturing suites and analytical laboratories at the Denver location are ideal for the development of small molecule APIs, particularly those with unique manufacturing challenges such as potent compounds, controlled substances, and small molecule conjugates.

Cedarburg Hauser specializes in the development and manufacturing of small molecule APIs. We leverage a talented group of scientists and supporting-staff, as well as a centralized approach to project management, to ensure on-time and on-budget completion of projects involving the development, scale-up, and manufacturing of complex APIs.

 

Company

Cedarburg Hauser Pharmaceuticals

870 Badger Circle
WI 53024 Grafton

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.